BIVV009-01 - Safety, Tolerability and Activity of BBIVV009 in Healthy Volunteers and Patients with Complement Mediated Disorders (BIVV009-01) Phase 1 Sanofi (Bioverativ) and Collaborators
http://clinicaltrials.gov/ct12/show/NCT02502903
Recruiting Last Updated Post December 18, 2019
Estimated Completion Date March 2021
BIVV020 - A Safety and Tolerability Study of BIVV020 in Adults with Cold Agglutinin Disease Phase 1 Sanofi Genzyme
https://clinicaltrials.gov/ct2/show/NCT04269551
Recruiting
Estimated Completion Date November 2021
BIVV009 - (Sutimlimab - press release May 14, 2020 ) A Study to Assess the Efficacy and safety of BIVV009 in Participants With Primary Cold Agglutinin Diseases Without A Recent History of Blood transfusion (Cadenza Study) Phase 3 Sanofi Genzyme
https://clinicaltrials.gov/ct2/show/NCT03347422
Active, Not Recruiting
Estimated Completion Date December 2021
We are writing to introduce ourselves and to share some exciting cold agglutinin disease (CAD) news.
Apellis is a development stage, global biopharmaceutical company that was established 10 years ago to combine courageous science, creativity, and compassion to deliver life-changing medicines for a broad range of serious diseases.
APL-2 - Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 (Pegcetacoplan) in Patients With wAIHA or CAD (Plaudit Study) Phase 2
Apellis Pharmaceuticals https://clinicaltrials.gov/ct2/show/NCT04269551
Active, Not Recruiting Last Updated Post February 7, 2020
Estimated Completion Date December 2020
Ascend-Waiha
The purpose of the current study is to assess the efficacy and safety/tolerability of two dose regimens of RVT-1401 (currently known as IMVT-1401) in the treatment of patients who have failed or not tolerated at least one prior treatment for WAIHA. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in IgG and other exploratory biomarkers.
https://ascendwaihastudy.com/ and the trial video below.
